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Abstract
This review summarizes recent investigations into antimalarial drug resistance and chemotherapy,
including reports of some of the many exciting talks and posters on this topic that were presented at
the third Molecular Approaches to Malaria meeting held in Lorne, Australia, in February 2008 (MAM
2008). After surveying this area of research, we focus on two important questions: what is the
molecular contribution of pfcrt to chloroquine resistance, and what is the mechanism of action of
artemisinin? We conclude with thoughts about the current state of antimalarial chemotherapy and
priorities moving forward.
The search for new antimalarials
For decades, malaria chemotherapy has relied on a limited number of drugs. However, the
acquisition and spread of drug resistance has led to an increase in morbidity and mortality rates
in many malaria-endemic regions. This increasing burden caused by drug-resistant parasites
has stimulated investigators to seek out novel antimalarial inhibitors and drug targets, and to
define the genetic basis of resistance to existing drugs, as a means to facilitate detection and
develop novel strategies to overcome resistance.
Targeting chromatin-modifying enzymes
The post-genomic era has ushered in a renewed focus on mechanisms of gene regulation in
Plasmodium, driven largely by investigations into the process of allelic exclusion in the var
gene family [1]. These have revealed a key role for the Plasmodium falciparum histone
deacetylase (HDAC) Sir2, the function of which in dynamic chromatin remodeling is
intimately associated with var gene silencing [2,3]. Earlier studies had identified HDAC
inhibitors (Table 1) that had moderate potency against cultured P. falciparum parasites in
vitro and rodent malaria parasites in vivo (see, for example, Ref. [4]). At MAM 2008, Kathy
Andrews (Queensland Institute of Medical Research, Australia) and colleagues reported highly
potent in vitro inhibitors, with IC50 values as low as 3 nM, which possess high selectivity for
P. falciparum compared to mammalian cells [5]. These inhibitors hyperacetylate parasite
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histones and produce an altered RNA-expression profile for some P. falciparum genes. Zbynek
Bozdech (Nanyang Technological University, Singapore) reported similar findings with the
HDAC inhibitor apicidin (abstracts for these and other studies reported at MAM 2008 appear
in a Supplement to the Int. J. Parasitol.)*.
The apicoplast – how good a target?
Additional novel drug targets are thought to reside within the parasite apicoplast, an organelle
ancestrally related to chloroplasts [6]. In describing these, Geoff McFadden (University of
Melbourne, Australia) discussed the apicoplast type II fatty acid synthesis pathway, which has
been postulated to be the target of several microbicides including triclosan and thiolactomycin
[6]. Groups led by David Fidock (Columbia University, New York, NY) and Stefan Kappe
(Seattle Biomedical Research Institute, Seattle, WA) have recently found that, unexpectedly,
this pathway is non-essential in asexual blood stages but is key to the development of infectious
liver-stage forms. A more promising apicoplast pathway for the development of an effective
blood-stage antimalarial is that of isoprenoid biosynthesis. Proof of principle has been achieved
already with the demonstration that fosmidomycin, an inhibitor of the isoprenoid enzyme 1-
deoxy-D-xylulose 5-phosphate (DOXP) reductase, can clinically cure P. falciparum infection
either with extended monotherapy or as a component of shorter-duration combination therapies
[7]. The challenge is to identify fosmidomycin analogs that have a more suitable
pharmacokinetic profile. For now, the most clinically useful apicoplast-specific antimalarials
are the antibiotics, such as clindamycin, tetracycline and azithromycin, that target protein
translation. These antibacterials, which produce a ‘delayed death’ phenotype with
Plasmodium parasites, have proven to be fairly effective components of antimalarial
combinations [6,8]. In vitro resistance to azithromycin, however, can be acquired readily with
P. falciparum asexual blood-stage cultures [9]. To make these antibiotic classes more effective
as antimalarials will require analog synthesis programs that can identify compounds with
greater potency and a reduced propensity to succumb to resistance.
Parasite metabolism
Inhibitors that arrest parasite metabolism or transport processes are now attracting considerable
interest. One area is vitamin biosynthesis, which occurs in P. falciparum but is absent in
humans. Carsten Wrenger (Bernhard Nocht Institute for Tropical Medicine, Hamburg,
Germany) presented the development of prodrugs that upon activation by pyridoxine kinase
can inhibit pyridoxal phosphate. Another pathway currently being targeted is the biosynthesis
of coenzyme A from the precursor pantothenate (vitamin B5). Kevin Saliba and his group
(Australian National University, Canberra, Australia) have now identified analogs of
pantothenate that possess selective antimalarial activity, with IC50 values of 15 µM or higher
[10].
Parasite transporters
Transporters involved in nutrient acquisition from the host are also under investigation as
candidate targets. Enrique Salcedo from the group of Patrick Bray (Liverpool School of
Tropical Medicine, UK) reported that the parasite-encoded folate-biopterin transporters
PfFBT1 and PfFBT2 can be inhibited by the dihydrofolate reductase inhibitor metho-trexate
and the organic anion transporter inhibitor probenecid. Folic acid uptake can also be inhibited
by the folate precursor para-amino benzoic acid, indicating a wide spectrum of substrates for
these two parasite transporters. An association between energy-dependent uptake of folates
and mitochondrial processes has also been observed by Ping Wang in the group of John Hyde
(University of Manchester, UK), based on studies with compounds known to inhibit
*MAM 2008, Lorne, Australia, Int. J. Parasitolol. 38, Suppl. 1, S1–S138.
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mitochondrial processes in other systems (see Ref. [11] and data reported at MAM 2008)*.
Sanjeev Krishna (St. George’s Hospital Medical School, London, UK) and Kevin Saliba are
also exploring inhibitors of the hexose transporter PfHT [12,13] and the P. falciparum V-type
H+-ATPase [14], respectively.
Choline biosynthesis
Unquestionably, the most advanced antimalarial drug development program targeting parasite
metabolism relates to inhibition of de novo phosphatidylcholine biosynthesis (Figure 1). This
program, spearheaded by Henri Vial (CNRS and University of Montpellier, France), has
identified choline analogs that inhibit P. falciparum asexual blood stages at single-digit
nanomolar concentrations [15]. Proof of fully curative antimalarial activity with short-course
treatments has been obtained in rodents and non-human primates infected at high parasitemias
[16,17]. These compounds are thought to inhibit choline transport and also exert an effect on
parasite phospholipid biosynthesis. These multiple modes of action, distinct from current
antimalarial agents, are a major strength of these inhibitors [18] because they could help delay
the development of resistance. Human clinical trials with this exciting new class of compounds
are currently under way, operated by Sanofi-Aventis (H. Vial, personal communication).
Inhibition of mitochondrial enzymes
Compounds that inhibit pyrimidine de novo biosynthesis also provide promise for future
development. Major efforts in this direction are being applied to dihydroorotate dehydrogenase
(DHODH), a key flavin mononucleotide-dependent mitochondrial enzyme that utilizes
coenzyme Q as the final electron acceptor [19,20]. Margaret Phillips (UT Southwestern
Medical Center, Dallas, TX) and colleagues recently have identified several potent, species-
selective inhibitors of PfDHODH [21]. These inhibitors display IC50 values in the range 20–
600 nM and Exhibit 200–20 000-fold selectivity for the malarial over the human enzyme. These
completely block the Q-dependent oxidation of flavin mononucleotide, indicating that they act
upon the electron transfer pathway between flavin mononucleotide and coenzyme-Q [22].
Giancarlo Biagini and Steve Ward (Liverpool School of Tropical Medicine, Liver-pool, UK)
have also identified a new class of mitochondrial inhibitors, known as dihydroacridinediones.
These inhibitors target the quinol oxidation site (Qo) of the parasite mitochondrion bc1
complex, causing a collapse of the mitochondrion membrane potential and cell death, and
display selectivity against the parasite enzyme that is ~5000-fold higher than for human liver
bc1 [23].
Inhibition of parasite invasion of red blood cells
Drugs could also potentially be designed that inhibit parasite invasion of host red blood cells
(RBCs). One mechanism of parasite invasion involves the microneme protein EBA-175, which
recognizes host-cell sialic-acid-containing glycophorin A [24–26]. Using NMR spectroscopic
techniques and molecular modeling, Mark von Itzstein and colleagues (Griffith University,
Queensland, Australia), are exploring the possibility of using neuraminic acid derivatives to
compete for sialic acid recognition by EBA-175. Perturbation of this interaction might decrease
or prevent parasite invasion of host RBCs.
Inhibition of parasite proteases
The falcipain and plasmepsin families of cysteine and aspartic proteases, respectively, which
are involved in parasite-mediated hemoglobin digestion in the digestive vacuole (DV) of intra-
erythrocytic parasites, have long been defined as promising drug targets [27,28]. In
collaboration with Philip Rosenthal (University of California, San Francisco, CA), scientists
at GlaxoSmithKline (Tres Cantos, Spain) have identified inhibitors of falcipains 2 and 3 that
prevent in vitro P. falciparum growth at low nanomolar concentrations. These inhibitors can
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also cure P. falciparum infections propagated in vivo in human RBCs in a new
immunocompromised mouse model [29]. Drug discovery efforts focused on the plasmepsin
enzymes have lessened after the discovery of ten plasmepsin paralogs in the P. falciparum
genome and the finding that parasites can survive, albeit with a reduced growth rate, without
all four plasmepsins of the DV [30,31]. Recent studies by Dan Goldberg (Washington
University School of Medicine, St. Louis, MO) now reveal substantial redundancy within and
between these two hemoglobinase families and show that the plasmepsin zymogens can be
cleaved and activated by falcipains or autoactivated in the presence of falcipain inhibitors
[32]. Interestingly, HIV protease inhibitors, which are believed to target one or more parasite
aspartic proteases, have been found to be effective against malarial infection. Kathy Andrews
and Tina Skinner-Adams (Queensland Institute of Medical Research, Australia) presented their
data with HIV protease inhibitors tested against P. falciparum in vitro or Plasmodium chabaudi
in vivo (reviewed in Ref. [33]). These findings are particularly promising in light of the growing
use of these protease inhibitors for the treatment of HIV in malaria-endemic regions.
Emerging technologies
The ability to identify new drug targets and antimalarial compounds through large-scale screens
is rapidly improving with emerging high throughput technologies. Vicky Avery (Griffith
University, Queensland, Australia) and colleagues are using a DAPI nuclear dye-based high-
throughput confocal imaging assay to screen natural product libraries for whole-cell
antimalarial activity and have identified several plant extracts with micromolar activities
[34]. Whole-cell assays using fluorescence-activated cell sorting analysis of a green
fluorescence protein-expressing P. falciparum line are also being developed by Chairat
Uthaipibull (National Center for Genetic Engineering and Biotechnology, Bangkok, Thailand)
in collaboration with Brendan Crabb (the Burnet Institute, Melbourne, Australia) and Alan
Cowman (The Water and Eliza Hall Institute, Melbourne, Australia), as part of the WHO TDR-
supported Transfection Network. Elizabeth Winzeler (Genomics Institute of the Novartis
Research Foundation and The Scripps Research Institute, La Jolla, CA) and colleagues have
also developed a 1536-well, SYBR green I fluorescence-based parasite proliferation assay that
was used to screen a Novartis collection of 2.6 million chemically diverse compounds,
producing more than 9000 active antimalarial hits [35].
Powerful new ‘omic’ technologies are also being developed to explore drug mode of action
and resistance. A quantitative proteomics approach [36], developed by the group of John Yates
III (The Scripps Research Institute, La Jolla, CA), is being used to identify parasite proteins
that have expression levels that are altered in response to chloroquine (CQ) or artemisinin
treatment. Joe DeRisi (University of California, San Francisco, CA) has also developed high-
throughput platforms for selecting drug-resistant P. falciparum mutants and is screening for
transcriptional or sequence changes using microarrays and Solexa sequencing. Sarah Volkman
and Dyann Wirth (Harvard School of Public Health, Boston, MA) are developing an extensive
genome-wide map of P. falciparum genetic diversity that has identified over 93 000 single
nucleotide polymorphisms and can detect selective sweeps of drug resistance determinants
(such as pfcrt) and define parasite population structures [37]. This work also produced a
molecular barcode, based on 24 PCR primer pairs, which ascribes a unique genotype to any
strain. This technology has tremendous potential to identify genes associated with emerging
drug resistance.
PfCRT and chloroquine resistance
Multiple laboratory and clinical studies illustrate the central role that PfCRT has in mediating
chloroquine resistance (CQR) [38]. How this is achieved mechanistically, and to what extent
other parasite factors contribute to resistance, remains an active area of exploration. CQ
accumulates in the acidic parasite DV by virtue of its weak base properties. There, it is thought
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to act by binding to toxic heme species, which form during hemoglobin degradation, and
inhibiting their detoxification. The CQR phenotype, which is reversible by verapamil, is
associated with decreased uptake of CQ in the DV [39]. Previous transfection experiments
have shown that mutant pfcrt alleles can confer CQR to a CQ-sensitive (CQS) strain (tested
with GC03) and that resistance is dependent on the presence of the PfCRT K76T mutation
[40,41].
How do PfCRT mutations lead to CQR? Kiaran Kirk (Australian National University,
Canberra, Australia) summarized evidence indicating that pfcrt-mediated CQR is a result of
increased drug efflux from the DV, by mechanisms that evoke either a carrier or a channel
[42–45]. Bioinformatic comparisons with members of the drug–metabolite transporter
superfamily [46] and studies in Xenopus laevis oocytes expressing PfCRT indicate that the loss
of the positive charge resulting from the K76T mutation enables the protonated drug to traverse
the transporter, leading to the movement of drug back into the parasite cytoplasm. This drug
translocation is sensitive to verapamil. When the proton pump of the parasite is inhibited by
concanamycin A, CQ causes a verapamil-sensitive increase in the rate of DV alkalinization of
CQR strains, indicating that CQ efflux is associated with protons [47] (Figure 2).
However, PfCRT mutations are not the full story. Using a transfection-based approach,
Stephanie Valderramos and David Fidock (Columbia University, New York) recently have
obtained definitive evidence that the genetic background of the host strain determines the extent
to which mutant pfcrt exerts CQR. This finding confirms earlier indications obtained with
genetically diverse field isolates or culture-adapted lines (reviewed in Ref. [48]). The most
unusual response was observed with the transfected D10 clone engineered to express mutant
pfcrt, in that its decreased susceptibility to CQ was most pronounced at the IC90 level (i.e. the
concentration of drug that inhibits 90% of growth relative to untreated control) and not the
IC50 level. Further experiments revealed that depending on the strain, mutant pfcrt confers
either resistance or a state of tolerance, implying that other factors must contribute to enable
certain strains to acquire high-level resistance in the presence of mutant pfcrt.
Point mutations or changes in the levels of expression of the pfmdr1 gene product Pgh1 can
also affect the P. falciparum CQR phenotype in a strain-dependent manner [49–52]. Recent
studies by David Johnson and Steve Ward have provided evidence that Pgh1 expression can
be increased upon parasite exposure to the anticonvulsant phenobarbitone (Figure 2), which
causes decreased in vitro CQ susceptibility in both CQR and CQS parasites [53]. This effect
is distinct from other studies in which Pgh1 overexpression has been associated with increased
CQ susceptibility [54]. In the Johnson study, putative nuclear-receptor-binding sites with
homology to mammalian sequences activated by phenobarbitone were identified in the
pfmdr1 and pfcrt promoter regions, and several putative nuclear receptor genes were identified.
These findings raise the novel hypothesis that nuclear-receptor-mediated responses to drug
exposure might be a mechanism of gene regulation in P. falciparum [53].
Whereas CQ-resistant strains of P. falciparum have spread throughout virtually all malaria-
endemic areas, CQR in Plasmodium vivax remains relatively rare and is restricted mostly to
Indonesia, Irian Jaya and other countries in the Pacific region. The genetic basis of P. vivax
CQR has remained elusive and does not seem to involve pvcg10, the P. vivax ortholog of
pfcrt [55]. Simon Kang’a and others in the group of Jane Carlton (New York University
Medical Center, New York, NY) recently surveyed variation across 36 microsatellite markers
in 19 CQ-resistant and 21 CQS P. vivax samples from patients in Indonesia. Their preliminary
analysis found no evidence of a selective sweep in the resistant isolates and revealed a low
level of genetic diversity overall. Ric Price (Menzies School of Health Research, Darwin,
Australia) adopted an alternative approach that employed an optimized P. vivax in vitro
schizont maturation assay applied to P. vivax isolates from Papua and Thailand. Genotyping
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analysis of pvmdr1 revealed an association between CQR and a novel Y976F mutation [56].
Their data also supported an association between pvmdr1 amplification and reduced
mefloquine susceptibility, reminiscent of the well-established association between pfmdr1
amplification and reduced mefloquine susceptibility [57]. Kasia Modrzynska (University of
Edinburgh, UK) has also been pursuing genetic linkage studies with CQ-resistant lines of P.
chabaudi. These studies found no association with the orthologs of pfcrt or pfmdr1 and resulted
in the unexpected finding that mutations in the deubiquitinating enzyme UBP-1 occurred in
parasites pressured extensively with chloroquine (or artesunate) [58]. Defining the alternative
mechanisms of CQR that prevail in other Plasmodium species will be important for a more
complete understanding of how resistance to this drug is acquired and mediated.
Many questions remain about CQR and CQ treatment failures in humans. Johan Ursing
(Karolinska Institute, Stockholm, Sweden) recently reported findings from Guinea-Bissau that
CQ, at double doses, was highly effective – curing 78% of uncomplicated malaria patients
harboring pfcrt K76T genotypes [59]. This raises the question of the relative importance of
pharmacokinetics vs genetics as causes of drug failure. Questions about the relationship
between fitness costs imposed by mutant pfcrt, the dynamics of mixed infections and the level
of local CQ use have also been raised recently by Qin Cheng (Australian Army Malaria
Institute, Enoggera, Queensland), who found that mutant pfcrt was decreasing in prevalence
far more slowly in Hainan Island, China [60] than in Malawi [61] after the cessation of CQ use
to treat P. falciparum malaria. Importantly, the returning CQS parasites have wild-type pfcrt
and are genetically diverse.
Identification of the PfCRT K76T mutation by PCR has been used widely to identify CQR and
has been proven to be a highly sensitive marker [62]. However, results need to be interpreted
with caution, especially in high-transmission settings, where individual patients tend to be
infected with many genetically distinct P. falciparum variants. Steve Meshnick (University of
North Carolina, Chapel Hill, NC) has applied heteroduplex tracking assays (HTAs) to describe
this internal heterogeneity. HTAs can be used to quantify variants and detect minority variants
that represent as little as 1% of the population in a single host, in contrast to classical PCR
methods that can often be insensitive below 10–20%. Using HTA, his group was able to detect
the PfCRT K76T-bearing minority variants in ~25% of Malawian patients – all of whom
seemed (using classical PCR) to be infected only with wild-type parasites. HTA was also used
to detect rare instances of the DHFR I164L mutation in P. falciparum infections in Malawi
[63].
The mechanism of action of artemisinin
Artemisinin derivatives are the most important newclass of antimalarials and are in widespread
use. Studies into the cytotoxic effects of artemisinin derivatives have indicated that their
activity might be propagated by interactions between the endoperoxide bridge of the drug and
heme-iron, produced during hemoglobin degradation inside the DV. This iron has been
proposed to generate free radicals that alkylate and oxidize proteins and lipids within infected
RBCs (see Ref. [64] and references therein). This hypothesis is consistent with the finding that
artemisinin activity can be potentiated by oxygen and oxidizing agents and attenuated by
reducing agents [65]. However, this has been questioned by other studies. One proposed that
artemisinins are activated via reductive cleavage of the peroxide bond by intracellular iron–
sulfur redox centers, which are common to Plasmodium enzymes, and that alkylation of these
enzymes could result in parasite death [66]. Interestingly, incubation of parasite lysates with
radiolabeled artemisinin identified several interacting proteins, indicating that parasite death
might result fromthe alkylation and inactivation of parasite proteins [67,68]. Additional support
against the heme hypothesis is that artemisinins are effective against ring-stage parasites that
do not seem to have high concentrations of heme [69]. Specific proteins that have been
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proposed to be the target of artemisinins include cysteine proteases [70], proteins of the electron
transport chain [71], translationally controlled tumor protein [68] and PfATP6, a SERCA-type
Ca2+ATPase [72].
PfATP6 has received the most attention because its activity in transfected X. laevis oocytes is
abolished by artemisinin but is unaffected by other antimalarials. This includes the inactive
compound desoxyartemisinin, which lacks the endoperoxide bridge [72]. Additional studies
in X. laevis have reported that an L263E point mutation can abolish inhibition by artemisinins
[73]. Sanjeev Krishna summarized evidence from field studies and heterologous expression
systems that support a role for PfATP6 mutations in emerging artemisinin resistance [74]. To
test the role of the L263E mutation in parasite response to artemisinins, allelic exchange
experiments were carried out in the Fidock laboratory, in collaboration between the two groups.
The presentation included Krishna’s statistical analyses of IC50 values, which showed a skewed
distribution of artemisinin and dihydroartemisinin responses in the mutant recombinant
parasites expressing the L263E mutation, with some assays showing higher IC50 values in the
L263E mutants when the data were normalized to wild-type controls. The analysis of these
data is ongoing and the results are keenly awaited because the role of PfATP6 in artemisinin
susceptibility remains a topic of considerable debate.
Additional work investigating the mechanism of action of artemisinins was presented by Maria
del Pilar Crespo, working in the group of Leann Tilley (La Trobe University, Melbourne,
Australia), who provided evidence that artemisinin derivatives cause early disruption of the
parasite DV and do not seem to affect the structure of the endoplasmic reticulum (where
PfATP6 is presumably located). Using a proteomic approach, Sumalee Kamchonwongpaisan
(National Centre for Genetic Engineering and Biotechnology, Bangkok, Thailand) presented
evidence that artemisinins might affect parasite endocytosis of host proteins. Whether
artemisinin accumulation in the DV relates to its mode of action, and how PfATP6 might
contribute to artemisinin action and potential gain of resistance by Plasmodium parasites,
clearly requires further studies.
Concluding remarks
The increasing awareness of the problems posed by multi-drug-resistant malaria, and of the
need to understand the basis of resistance and develop new chemotherapeutic strategies and
drugs, has spurred a rapid increase in the volume of research being applied to this area. The
topics cited previously illustrate the tremendous gains that can be achieved through the
application of genetic, genomic, proteomic, biochemical, synthetic or medicinal chemistry, or
structural biology approaches. Today’s optimism that artemisinin-based combination therapies
provide a sustainable answer as to how to reduce malaria morbidity and mortality finds parallels
in earlier campaigns founded on CQ, the efficacy of which was once absolute. The elaboration
of a coordinated Worldwide Antimalarial Drug Resistance Network to identify emerging
resistance, spearheaded by Carol Sibley (University of Washington, Seattle, WA), is an
important initiative in this regard [75]. Ever more research in the area of antimalarial resistance
mechanisms and new chemotherapies must be supported to sustain the continuous stream of
discoveries needed to reduce the devastating impact of malaria across the inter-tropical regions
of the world.
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Mechanism of the antimalarial activity of the choline analog T3. This representative bis-
quaternary ammonium compound is thought to enter the infected erythrocyte through the new
permeation pathway or another (unknown) mechanism (represented by the question mark near
the RBC membrane). This choline analog is then taken up into the intraerythrocytic parasite
via an organic cation transporter present on the parasite plasma membrane. This perturbs
choline uptake from the host cell compartment, thus disrupting the synthesis of the predominant
membrane lipid, phosphatidylcholine. Additional effects on phosphatidylcholine biosynthesis
enzymes have also been proposed [16]. T3 and other biscationic compounds also accumulate
within the parasite, mostly in the digestive vacuole (DV, yellow) where they bind heme
(ferriprotoporphyrin IX). This heme interaction has also been hypothesized to contribute to
their antiplasmodial activity [18]. These compounds, therefore, might have multiple sites of
action within the parasite. CCT, phosphocholine cytidylyltransferase; CDP, cytidine
diphosphate; CK, choline kinase; CPT, choline phosphate transferase; Hz, hemozoin; P,
phosphate; RBC, red blood cell.
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Model of the chloroquine (CQ)-associated H+ leak observed in CQ-resistant P. falciparum
lines. The pH of the digestive vacuole (DV) reflects a balance between the inward H+ pumping
of the V-type H+-ATPase and the outward leak of H+ from the DV, via as yet uncharacterized
leak pathways (indicated by the boxed question mark). Upon inhibition of the V-type H+-
ATPase with concanamycin A, efflux of H+ via the leak pathways results in DV alkalinization.
The neutral form of CQ diffuses down a weak-base gradient and accumulates within the acidic
environment of the DV. Therein, CQ becomes mostly diprotonated and, hence, less membrane-
permeant. In CQ-resistant parasites (indicated by K76T), mutant PfCRT-mediated efflux of
protonated CQ might occur in symport with H+. Kirk and colleagues have hypothesized that
this constitutes a verapamil-sensitive H+ leak that is responsible for the CQ-associated increase
in the rate of alkalinization after inhibition of the parasite V-type H+-ATPase [47]. The circled
question mark denotes the possibility that the flux of H+ via mutated PfCRT underlies the
higher rate of alkalinization (after pump inhibition) seen in CQ-resistant parasites, as well as
the possibility that the efflux of CQ via mutated PfCRT might be a H+-coupled (and, therefore,
secondary active transport) process. The promoter regions of pfcrt and pfmdr1 have also been
proposed to contain phenobarbitone nuclear-receptor-binding sites, which suggests that
nuclear-receptor-mediated responses to drug exposure might alter the regulation of these genes
[53]. RBC, red blood cell. Adapted, with permission of the Company of Biologists, from Ref.
[47].
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Table 1
P. falciparum drug targets with active small molecule inhibitors currently under investigation
Cellular localization Target Refs
Apicoplast DOXP reductoisomerase [7]
Apicoplast gyrase [8]
Apicoplast protein synthesis [8]
Apicoplast transcription [8]
Fatty acid synthesis [76]
Cytosol Choline synthesis [17]
Coenzyme A biosynthesis [77]
Gamma-glutamylcysteine synthetase [76]








Vitamin B6 synthesis [83]
Dense granules Subtilisin-like proteases [84]
Digestive vacuole Cysteine/aspartic proteases [76]
Heme detoxification [85]
Membrane Folate-biopterin transport [86]
Hexose transport [12,13]
V-type H+-ATPase [14]
Host–parasite interactions during invasion [26]
Mitochondria Dihydroorotate dehydrogenase [21]
Mitochondrial bc1 complex [23]




Red blood cell Heterotrimeric G protein [89]
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